What a great week on the Catalyst! We heard several different perspectives on incremental innovation and the value that medicines provide to millions of patients suffering from disease.
A recent report from the IFPMA (the International Federation of Pharmaceutical Manufacturers and Associations) adds to the growing body of work on the cumulative, step-wise nature of biopharmaceutical progress, with a particular focus on incremental innovatio
If you're not worried by dementia - its personal cost and its economic toll - you should be. I am. Anyone who, like me, has had a family member die with dementia understands the devastation: the years - if not decades - of the living loss of a loved one; the drain on family and healthcare resources; the unmet hope that something may be done to relieve or reverse the insidious progress of the condition.
Eric A. Utt, Ph.D., Director, Worldwide Policy for Pfizer, wraps up the second of a two-part series on incremental innovation. During the 1940s and 1950s, tuberculosis patients were housed in sanitariums, frequently alongside patients who had been institutionalized with various mental illnesses. At this time, mental disorders such as schizophrenia and depression were not accessible to effective drug treatments.
A recent op-ed in Forbes offers a welcome rebuttal to misguided criticism of the conduct of clinical trials by the biopharmaceutical industry by refuting the notion that "medicine is broken" partly due to the hiding of "negative" clinical trial results.
As part of our ongoing incremental innovation series on the Catalyst, Thomas F. Goss, PharmD, Senior Vice President, Boston Healthcare Associates, highlights the importance of medical progress for patients suffering from rheumatoid arthritis in his very own blog post: The weather is warming (finally) here in the northeast, and like many families, we found ourselves enjoying the warm outdoor weather this past weekend.
The pharmaceutical supply chain can remain the safest in the world, but only if we make the right changes to protect patients. Now more than ever before, patient safety requires urgent action to protect patients from counterfeit medicine and bad actors.
In the U.S., we are fortunate to have a dynamic, collaborative biomedical research ecosystem that encompasses ideas and persistence of researchers across government, industry and academia. It's a tremendous national resource that greatly benefits both the health of our people and our economy. And it's one that we must continue to nurture and support.
David Grainger, Global Public Policy Director, Eli Lilly and Company, is sharing with us a blog post he wrote about the value of innovative treatments for cancer, Health Technology Assessment and the overall theme of incremental innovation - which is a focus this week on the Catalyst:
Next week, we will convene leaders from the biopharmaceutical industry, the patient community, academia and beyond to discuss how we can all work together to advance research, progress and hope for the millions of patients who rely on innovative medicines.
We talk a lot about innovation in health care. This week on the Catalyst we’d like to take a step back and look at the big picture. What is innovation? How does it come about? How is biomedical innovation contributing to progress against serious and life-threatening diseases and conditions?
Today, we are pleased to have a guest blog post on incremental innovation from Eric A. Utt, Ph.D., Director, Worldwide Policy for Pfizer.